Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir® containing regimen

Journal of Clinical Virology

Volumn 33, Issue 3, 2005, Pages 188-193

  Matsushita, Shuzo ^a   Yoshimura, Kazuhisa ^a   Kimura, Tetsuya ^a   Kamihira, Asako ^b   Takano, Misao ^c   Eto, Kenichiro ^a   Shirasaka, Takuma ^b   Mitsuya, Hiroaki ^a   Oka, Shinichi ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Combivir; Hemoglobin; Lamivudine; Long term treatment; Neutrophil; Zidovudine

Indexed keywords

DIDANOSINE; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; ANEMIA; BLOOD TOXICITY; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG USE; FEMALE; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MOLECULAR MECHANICS; NAUSEA; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS LOAD; VOMITING;

EID: 19344366685     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.11.002     Document Type: Article

References (21)

1. F. Dianzani, G. Antonelli, O. Turriziani, E. Riva, E. Simeoni, and C. Signoretti Zidovudine induces the expression of cellular resistance affecting its antiviral activities AIDS Res Hum Retroviruses 10 1994 1471 1478
2. J.P. Dieleman, M. Jambroes, I.C. Gyssens, M.C. Sturkenboom, B.H. Stricker, and W.M. Mulder Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort AIDS 16 2002 737 745
3. J.J. Eron, E.S. Yetzer, P.J. Ruane, S. Becker, G.A. Sawyerr, and R.L. Fisher Efficacy, safety, and adherence with a twice-daily combination of lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection AIDS 14 2000 671 681
4. A. Fridland, M.C. Connelly, and B.L. Robbins Cellular factors for resistance against antiretroviral agents Antiviral Ther 5 2000 181 185
5. B. Groschel, J. Cinatl, and J. Cinatl Jr. Viral and cellular factors for resistance against antiretroviral agents Intervirology 14 1997 400 407
6. J.A. Harrington, J.E. Reardon, and T. Spector 3′-Azido-3′- deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT terminated DNA Antimicrob Agents Chemother 37 1993 918 920
7. E.K. Hester, and J.E. Peacock Jr. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection AIDS 12 1998 439 440
8. S. Kimura, S. Oka, T. Toyoshima, Y. Hirabayashi, Y. Kikuchi, and K. Mitamura A randomized trial of reduced doses of azidothymidine in Japanese patients with human immunodefiency virus type 1 infection Intern Med 31 1992 871 876
9. S. Kimura, K. Yamada, A. Ito, J. Mimaya, J. Takamatsu 3TC Study Group Phase 2 clinical study on 3TC (Lamivudine) in HIV infections Antibiot Chemother 14 1998 1419 1432
10. A. Moses, J. Nelson, and G.C. Bagby Jr. Review article: the influence of human immunodeficiency virus-1 on hematopoiesis Blood 91 1998 1479 1495
11. D.D. Richman, M.A. Fischl, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, and O.L. Laskin The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial N Engl J Med 317 1987 192 197
12. J.D. Schuetz, M.C. Connelly, D. Sun, S.G. Paibir, P.M. Flynn, and R.V. Srinivas MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs Nat Med 5 1999 1048 1051
13. M.J. Sibery, A. Astrow, S. Kempin, and I. Halperin Combivir (AZT/3TC) therapy is associated with life-threatening anemia in patients with HIV infection Blood 102 2003 51b (Abstract 3907)
14. J.P. Sommadossi, R. Carlisle, and Z. Zhou Cellular pharmacology of 3-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells Mol Pharmacol 36 1989 9 14
15. Y. Tornevik, B. Ullman, J. Balzarini, B. Wahren, and S. Eriksson Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells Biochem Pharmacol 49 1995 829 837
16. A. Tseng, J. Conly, D. Fletcher, D. Keystone, I. Salit, and S. Walmsley Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy Clin Infect Dis 27 1998 908 909
17. O. Turriziani, G. Antonelli, and F. Dianzani Cellular factors involved in the induction of resistance of HIV to antiretroviral agents Int J Antimicrob Agents 16 2000 353 356
18. J. Wijnholds, C.A. Mol, L. van Deemter, M. de Haas, G.L. Scheper, and F. Baas Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs Proc Natl Acad Sci USA 97 2000 7476 7481
19. M.I. Wilde, and H.D. Langtry Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy Drugs 46 1993 515 578
20. J.P. Yan, D.D. Ilsley, and C. Frohlick 3′-Azidothymidin (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations J Biol Chem 270 1995 22836 22841
21. P.G. Yeni, S.M. Hammer, C.C.J. Carpenter, D.A. Cooper, M.A. Fischl, and J.M. Gatell Antiretroviral treatment for adult HIV infection. 2002. Updated recommendation of the International AIDS Society-USA Panel JAMA 288 2002 222 235